Long-term Efficacy, Safety, and Immunogenicity Data From a Phase III Confirmatory Study Comparing GP2017, a Proposed Biosimilar, With Reference Adalimumab

Authors :: Julia Jauch-Lembach
Alison Balfour
Joseph F. Fowler
Jean-Phillippe Lacour
Craig L. Leonardi
Andrew Blauvelt
Ellen Schuck
Source :: American Journal of Gastroenterology. 112:S419
Publication Year :: 2017
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2017.

Subjects :: 030203 arthritis & rheumatology
Oncology
medicine.medical_specialty
Hepatology
business.industry
Immunogenicity
Gastroenterology
Biosimilar
Term (time)
03 medical and health sciences
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
Adalimumab
business
medicine.drug

Full Text Access

Tools